导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.11% | 3492/4773 |
| 近一周 | -1.77% | 716/5462 |
| 近一月 | -2.42% | 1261/5421 |
| 近一季 | -5.59% | 1879/5209 |
| 近半年 | -3.61% | 2262/4920 |
| 近一年 | -7.18% | 3212/4366 |
| 近两年 | 43.91% | 1694/2954 |
| 近三年 | 33.69% | 909/2253 |
| 成立以来 | 31.99% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.93% 4252/4961 |
7.69% 2676/5312 |
- - |
- - |
| 2025 | 25.14% 1733/4813 |
5.50% 771/3635 |
2.35% 1627/4076 |
19.79% 2097/4524 |
-3.26% 3266/4813 |
| 2024 | 22.28% 385/3463 |
0.34% 994/2808 |
3.43% 270/3014 |
20.66% 682/3129 |
-2.35% 2054/3463 |
| 2023 | -10.38% 1299/2656 |
2.77% 1302/2280 |
-2.04% 556/2385 |
-6.04% 1420/2515 |
-5.26% 1308/2655 |
| 2022 | -19.33% 835/2207 |
-15.88% 1079/1919 |
5.37% 913/2016 |
-16.90% 1518/2113 |
9.52% 213/2208 |
| 2021 | -9.82% 1084/1822 |
-2.97% 735/1255 |
1.89% 1032/1330 |
-10.11% 1212/1466 |
1.48% 908/1822 |
| 2020 | 32.45% 483/1250 |
-9.03% 651/1028 |
19.63% 295/1067 |
7.71% 763/1164 |
13.00% 403/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银粤港澳大湾区创新100ETF VS. 长安沪深300非周期A(740101) |